CD8A and cancer: Programmed death‐1 receptor (PD‐1) ligand (PD‐L1) and CTL‐associated antigen 4 (CTLA‐4) are checkpoint receptors that can be targeted to re-activate anticancer CD8+ T-cell responses in cancer-immune therapy33.